An ex-FDA consumer safety officer discussed the challenges of navigating policy and politics in rare diseases at a recent meeting.Recent changes at the US Food and Drug Administration (FDA) have changed the circumstances for rare disease drug development, but this remains an area of opportunity for biotechs.At the recent 3rd Annual Clinical Trials in Rare […]
